Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy

International Journal of Cancer

Volumn 135, Issue 4, 2014, Pages 880-886

  Hesselink, A T ^a   Heideman, D A M ^a   Steenbergen, R D M ^a   Gok M ^a   Van Kemenade, F J ^a   Wilting, S M ^a   Berkhof, J ^a   Meijer, C J L M ^a   Snijders, P J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

cervical cancer; cervical scrapes; CIN; DNA methylation; HPV; qMSP; self sampling; tumor suppressor genes

Indexed keywords

MYELIN AND LYMPHOCYTE PROTEIN;

ARTICLE; CANCER SCREENING; CELL ADHESION MOLECULE 1 GENE; COLPOSCOPY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; DNA METHYLATION ASSAY; FEMALE; GENE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MAL GENE; MICRORNA 124 2 GENE; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL LAVAGE;

CERVICAL CANCER; CERVICAL SCRAPES; CIN; DNA METHYLATION; HPV; QMSP; SELF-SAMPLING; TUMOR SUPPRESSOR GENES;

ADULT; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; DNA METHYLATION; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; GENETIC TESTING; GENOTYPE; HUMANS; IMMUNOGLOBULINS; MICRORNAS; MIDDLE AGED; MYELIN AND LYMPHOCYTE-ASSOCIATED PROTEOLIPID PROTEINS; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84902258621     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28723     Document Type: Article

References (50)

1. Anttila A, Pukkala E, Soderman B, et al. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer 1999; 83: 59-65.
2. Quinn M, Babb P, Jones J, et al. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999; 318: 904-8.
3. de Kok I, van der Aa MA, van BM, et al. Trends in cervical cancer in the Netherlands until 2007: has the bottom been reached? Int J Cancer 2011; 128: 2174-81.
4. Weller DP, Campbell C,. Uptake in cancer screening programmes: a priority in cancer control. Br J Cancer 2009; 101 Suppl 2: S55-S59.
5. Raab SS, Grzybicki DM, Zarbo RJ, et al. Frequency and outcome of cervical cancer prevention failures in the United States. Am J Clin Pathol 2007; 128: 817-24.
6. Bos AB, Rebolj M, Habbema JD, et al. Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer 2006; 119: 2372-5.
7. Gok M, Heideman DA, van Kemenade FJ, et al. Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: characteristics of the responders. Eur J Cancer 2012; 48: 1799-808.
8. Peto J, Gilham C, Fletcher O, et al. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 249-56.
9. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-88.
10. Naucler P, Ryd W, Tornberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009; 101: 88-99.
11. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012; 13: 78-88.
12. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249-57.
13. Gok M, Heideman DA, van Kemenade FJ, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 2010; 340: c1040.
14. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011; 378: 1868-73.
15. Zhao FH, Lewkowitz AK, Chen F, et al. Pooled analysis of a self-sampling HPV DNA test as a cervical cancer primary screening method. J Natl Cancer Inst 2012; 104: 178-88.
16. Gyllensten U, Sanner K, Gustavsson I, et al. Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer. Br J Cancer 2011; 105: 694-7.
17. Gok M, van Kemenade FJ, Heideman DA, et al. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program. Int J Cancer 2012; 130: 1128-35.
18. Snijders PJ, Verhoef VM, Arbyn M, et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 2013; 132: 2223-36.
19. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30 Suppl 5: F88-F99.
20. Dijkstra M, van ND, Rijkaart D, et al. Primary hrHPV DNA testing in Cervical Cancer screening: how to manage screen positive women? A POBASCAM Trial sub study. Cancer Epidemiol Biomarkers Prev 2014; 23: 55-63.
21. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012; 130: 602-10.
22. Petry KU, Schmidt D, Scherbring S, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol 2011; 121: 505-9.
23. Brink AA, Meijer CJ, Wiegerinck MA, et al. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol 2006; 44: 2518-23.
24. Garcia F, Barker B, Santos C, et al. Cross-sectional study of patient- and physician-collected cervical cytology and human papillomavirus. Obstet Gynecol 2003; 102: 266-72.
25. Yoshida T, Sano T, Takada N, et al. Comparison of self-collected and clinician-collected materials for cervical cytology and human papillomavirus genotyping: analysis by linear array assay. Acta Cytol 2011; 55: 106-12.
26. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol 2002; 55: 435-9.
27. Bulkmans NW, Bleeker MC, Berkhof J, et al. Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer 2005; 117: 177-81.
28. Castle PE, Stoler MH, Wright TC Jr, et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011; 12: 880-90.
29. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-9.
30. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 621-32.
31. Snellenberg S, Schutze DM, Claassen-Kramer D, et al. Methylation status of the E2 binding sites of HPV16 in cervical lesions determined with the Luminex(R) xMAP system. Virology 2012; 422: 357-65.
32. Mirabello L, Schiffman M, Ghosh A, et al. Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer 2013; 132: 1412-22.
33. Wentzensen N, Sherman ME, Schiffman M, et al. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009; 112: 293-9.
34. Overmeer RM, Henken FE, Snijders PJ, et al. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol 2008; 215: 388-97.
35. Steenbergen RD, Kramer D, Braakhuis BJ, et al. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst 2004; 96: 294-305.
36. Overmeer RM, Henken FE, Bierkens M, et al. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J Pathol 2009; 219: 327-36.
37. Wilting SM, van Boerdonk RA, Henken FE, et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer 2010; 9: 167.
38. Bierkens M, Hesselink AT, Meijer CJ, et al. CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer 2013; 133: 1293-9.
39. Hesselink AT, Heideman DA, Steenbergen RD, et al. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 2011; 17: 2459-65.
40. Eijsink JJ, Yang N, Lendvai A, et al. Detection of cervical neoplasia by DNA methylation analysis in cervico-vaginal lavages, a feasibility study. Gynecol Oncol 2011; 120: 280-3.
41. van den Brule AJ, Pol R, Fransen-Daalmeijer N, et al. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002; 40: 779-87.
42. Overmeer RM, Louwers JA, Meijer CJ, et al. Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int J Cancer 2011; 129: 2218-25.
43. Jin H, Lu Y,. The ROC region of a regression tree. Stat Probab Lett 2008; 79: 936-42.
44. Wikstrom I, Lindell M, Sanner K, et al. Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study. Br J Cancer 2011; 105: 337-9.
45. Virtanen A, Nieminen P, Luostarinen T, et al. Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol Biomarkers Prev 2011; 20: 1960-9.
46. Jentschke M, Lange V, Soergel P, et al. Enzyme-linked immunosorbent assay for p16(INK4a)-a new triage test for the detection of cervical intraepithelial neoplasia? Acta Obstet Gynecol Scand 2013; 92: 160-4.
47. Dutch Health Council. Trial register (www.gr.nl). 2012.
48. Lai HC, Lin YW, Huang TH, et al. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer 2008; 123: 161-7.
49. Feng Q, Balasubramanian A, Hawes SE, et al. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst 2005; 97: 273-82.
50. Sproul D, Kitchen RR, Nestor CE, et al. Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns. Genome Biol 2012; 13: R84.